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ABSTRACT
Objectives: Opioids modulate the perception of
breathlessness with a considerable variation in
response, with poor correlation between the required
opioid dose and symptom severity. The objective of
this hypothesis-generating, secondary analysis was to
identify candidate single nucleotide polymorphisms
(SNP) from those associated with opioid receptors,
signalling or pain modulation to identify any related to
intensity of breathlessness while on opioids. This can
help to inform prospective studies and potentially lead
to better tailoring of opioid therapy for refractory
breathlessness.
Setting: 17 hospice/palliative care services (tertiary
services) in 11 European countries.
Participants: 2294 people over 18 years of age on
regular opioids for pain related to cancer or its
treatment.
Primary outcome measures: The relationship
between morphine dose, breathlessness intensity
(European Organisation for Research and Treatment of
Cancer Core Quality of Life Questionnaire;
EORTCQLQC30 question 8) and 112 candidate SNPs
from 25 genes (n=588).
Secondary outcome measures: The same
measures for people on oxycodone (n=402) or fentanyl
(n=429).
Results: SNPs not in Hardy-Weinberg equilibrium or
with allele frequencies (<5%) were removed. Univariate
associations between each SNP and breathlessness
intensity were determined with Benjamini-Hochberg
false discovery rate set at 20%. Multivariable ordinal
logistic regression, clustering over country and
adjusting for available confounders, was conducted with
remaining SNPs. For univariate morphine associations,
1 variant on the 5-hydroxytryptamine type 3B (HTR3B)
gene, and 4 on the β-2-arrestin gene (ARRB2) were
associated with more intense breathlessness. 1 SNP
remained significant in the multivariable model: people
with rs7103572 SNP (HTR3B gene; present in 8.4% of
the population) were three times more likely to have
more intense breathlessness (OR 2.86; 95% CIs 1.46 to
5.62; p=0.002). No associations were seen with fentanyl
nor with oxycodone.
Conclusions: This large, exploratory study identified 1
biologically plausible SNP that warrants further study in
the response of breathlessness to morphine therapy.
INTRODUCTION
Breathlessness that persists despite disease-
modifying treatment (refractory breathless-
ness) is a major clinical problem internation-
ally.1 2 Chronic causes include respiratory
disease (mainly chronic obstructive pulmon-
ary disease (COPD) and interstitial lung
disease), cardiac failure, progressive neuro-
logical disorders, cancers and cachexia in
any late-stage disease.3–5 Symptom control is
a key priority for people with a life-limiting
illness as well as for their caregivers.6
Experimental studies of people with COPD
and in healthy volunteers have shown that
endogenous and exogenous opioids modulate
the perception of breathlessness intensity
without diminishing the ability to breathe
during exercise or with resistive loads.7–9 In
phase III clinical trials, the regular and system-
atic use of low doses of morphine (≤30 mg
morphine/24 h) have been shown to safely
reduce chronic refractory breathlessness inten-
sity by a clinically meaningful extent.10–14
In the only formal dose-ranging study of
opioids for the reduction of breathlessness
intensity, the opioid dose needed to relieve
breathlessness is highly individual, with a
threefold difference of the dose required to
relieve breathlessness, and where there was
Strengths and limitations of this study
▪ This is the first study that seeks to identify any
candidate single nucleotide polymorphisms that
help to predict differences in breathlessness
intensity while on morphine.
▪ This is a population-based study using rigorous
methodologies.
▪ The cohort used are taken from clinical practice
across a range of clinical settings and countries.
▪ There is no replication cohort in this study—this
is a topic for further work.
▪ This study has only sought signal from a bank of
candidate genes.
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only a weak association between the severity of breath-
lessness and the dose of low-dose, sustained-release mor-
phine providing relief.11 Clinicodemographic factors
predicting response of breathlessness intensity to opioids
from pooled data included higher baseline intensity of
breathlessness and younger age.15 In this analysis,
breathlessness intensity was not predicted by the domin-
ant aetiology of breathlessness, gender, functional status
nor descriptors of the breathlessness.15
Clinically, large interindividual variations are also seen
in the doses of opioids required to relieve pain in the
palliative care population. The European
Pharmacogenetic Opioid Study (EPOS), the largest such
study in the world (n=2294), failed to ﬁnd any single
nucleotide polymorphisms (SNPs) from 112 candidate
SNPs on 25 genes involved in opioid receptors, signal-
ling, nor pain-modifying functions that explained any of
the variations in the opioid dose required to achieve a
symptomatic response to opioids for pain.16 This was in
contrast with smaller studies which had identiﬁed several
SNPs purportedly inﬂuencing the dose–response rela-
tionship.16 To date, no studies exploring genetic variabil-
ity related to opioids and the palliation of refractory
breathlessness have been conducted.
The aim of this hypothesis-generating, secondary ana-
lysis of the EPOS data is to identify possible candidate
SNPs from a selection identiﬁed in the literature known
to be associated with opioid pharmacology in order to
inform future and prospective pharmacogenetic studies
of the response of refractory breathlessness to opioids.
This builds on the investigation of other key symptoms
for people at the end of life including pain, nausea and
cachexia from the same observational cohort.16–18
This study tests the null hypothesis that genetic varia-
tions in selected candidate SNPs related to opioid recep-
tors, signalling or pain-modifying functions are not
associated with the intensity of breathlessness in people
already treated with opioids for pain, assuming a similar
distribution of pain and breathlessness scores across the
population, and that opioid doses had been titrated to
clinical effect. Importantly, this study is not exploring
SNPs for breathlessness per se, or any relationship
between SNPs and response to opioids in breathlessness
intensity because of its cross-sectional design, but
instead, SNPs which may inﬂuence a relationship
between breathlessness intensity scores and opioids in
people already on opioids for pain.
METHODS
Methods have been outlined in detail in previous papers
from the group.16–18
Study setting
This cross-sectional study included 17 centres from 11
European countries.
In the subgroup of people using morphine with col-
lected breathlessness intensity scores (n=838), 112
candidate SNPs in 25 genes (table 1) with a putative
inﬂuence on opioid receptors, signalling or pain modu-
lation were evaluated for any association with breathless-
ness intensity scores, controlling for key factors that may
inﬂuence breathlessness intensity or response to opioids.
This analysis was repeated separately for people on fen-
tanyl (n=405) or oxycodone (n=429).
Study participants
Inclusion criteria were: age 18 years or over; conﬁrmed
diagnosis of cancer; and regular use of a WHO step 3
opioid for moderate or severe pain related to the cancer
or its treatment for more than 3 days. The only exclusion
criterion was the inability to use the language spoken in
the treating cancer centre.
Data collection
Between February 2004 and April 2008, cross-sectional
phenotypic data were collected on the cohort including
gender, age, weight, height, ethnicity, cancer diagnosis
and sites of metastatic disease, the European
Organisation for Research and Treatment of Cancer
Core Quality of Life Questionnaire (EORTC-QLQ-C30;
V.3.0)19 and performance status (Karnofsky Performance
Status scale).20 Data related to opioids included type of
opioid, total opioid dose in the 24 h prior to blood sam-
pling, duration of opioid therapy, and past use of other
opioids. Breathlessness intensity was evaluated from ques-
tion 8 in the EORTC QLQ-C30 on a four-point categor-
ical verbal rating scale (not at all; a little; quite a bit; or
very much) covering the person’s experience of the
symptom over the previous week, reﬂecting the sensory-
perceptual experience of the American Thoracic
Society’s recent statement on the Mechanisms,
Assessment and Management of Dyspnea.21
Specimen collection and analysis
A single specimen of whole blood was collected in an
EDTA tube at the time of questionnaire completion and
stored at –80°C before batched shipping to the HUNT
Biobank in Levanger, Norway. DNA was extracted using
Puregene blood kit (Qiagen Science, Germantown,
Maryland, USA) and using technology from Applied
Biosystems (Foster City, California, USA): the genotyping
was done using the SNPlex (dry DNA) Genotyping
System; capillary electrophoresis; gene mapping (V.4.0
software); and two SNPs (rs4680 and rs1045642) were
extracted using TaqMan SNP allelic discrimination.
Data analysis
Separate analyses were conducted for each of three
mutually exclusive populations (those who were pre-
scribed only one opioid: morphine, oxycodone, or fen-
tanyl), and for each of four modes of inheritance
(dominant, recessive, codominant and overdominant).
For each population, SNPs that were not in
Hardy-Weinberg equilibrium, or had minor allele fre-
quencies (<5%) were removed from the analysis, leaving
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112, 105 and 104 SNPs of interest in each of the mor-
phine, oxycodone and fentanyl populations, respectively.
Univariable associations between each SNP and the four-
point categorical rating scale for breathlessness were
determined using Fisher’s exact test. To control the
overall family-wise type I error rate (FWE) within each
mode of inheritance and for each opioid, we used
Benjamini-Hochberg (BH) multiple hypothesis testing
with a false discovery rate (FDR) set at 20%.22
The associations between breathlessness and any SNPs
identiﬁed as signiﬁcant using the BH procedure, within
each mode of inheritance and each opioid prescribed,
were then examined using multivariable ordinal logistic
regression, clustering over country, and adjusting for
age, gender, BMI, Karnofsky status, time on opioids,
opioid dose, pain levels and the SNPs identiﬁed by the
BH procedure. In order to ﬁt the model, it was neces-
sary to remove extraneous SNPs in high linkage disequi-
librium, with D'.0:95.23 The model reported did not
violate the proportional odds assumption for any of the
three opioids studied. For these analyses, a p value less
than 0.05 (two-tailed) is considered statistically
signiﬁcant.
All analyses were conducted using Stata V.13.1
(Statacorp, Texas, USA).
A properly constituted Research Ethics Committee at
each participating site approved the study, and each par-
ticipant provided written, informed consent.
The study is reported according to the STrengthening
the REporting of Genetic Association Studies (STREGA)
guidelines.24
RESULTS
The clinico-demographic factors for the 1672 partici-
pants in this substudy are outlined in table 1 for the
cohorts taking each of the three opioids.
Eight hundred and thirty-eight people were taking
morphine in whom viable samples were available for 588.
For these people, four variants on the β2 arrestin gene
(ARRB2) and one on the 5-hydroxytryptamine type 3B
(HTR3B rs7103572) gene were associated in univariable
analyses with breathlessness intensity (table 2). The geno-
typic frequency of each variant is also outlined (table 2).
Additionally, morphine dose and worsening functional
(Karnofsky) status were signiﬁcantly associated with more
intense breathlessness in univariable analyses (table 3).
In the multivariable model, three of the ARRB2 variants
were excluded as all variants were in high linkage disequi-
librium with Lewontin’s25 normalised linkage disequilib-
rium parameter D'.0:95 for each pair of SNPs (where a
value of D¼0 indicates independence and D¼1 complete
dependence of SNP frequencies).
Signiﬁcance was only maintained for the HTR3B
(rs7103572) and functional status (table 3). There was
no interaction between HTR3B (rs7103572) and opioid
dose. There were no signiﬁcant ﬁndings in the oxy-
codone or fentanyl cohorts.
The HTR3B (rs7103572) genotype frequency (TT)
was 8.2% of participants, with 52.8% CC and 39.1% CT.
The allele frequency was 72.3% (C) and 27.7% (T).
Other HTR3B SNPs tested included rs11214763,
rs11606194, rs1176744, rs2276307, rs3782025, rs1672717
and rs7943062.
Table 1 112 Predefined candidate single nucleotide polymorphisms (SNPs) in 25 genes with a putative influence on opioid
receptors, signalling and pain modulation: OPRM1, OPRD1, OPRK1, ARRB2, GNAZ, HINT1, Stat6, ABCB1, COMT, HRH1,
ADRA2A, MC1R, TACR1, GCH1, DRD2, DRD3, HTR3A, HTR3B, HTR2A, HTR3C, HTR3D, HTR3E, HTR1A, UGT2B7 or CNR1
Morphine (n=838) Fentanyl (n=405) Oxycodone (n=429)
Age (years) 62.1 (12.1) 63.5 (12.6) 62.3 (12.3)
Female gender 394 (47.0) 202 (49.9) 188 (43.8)
Body mass index (kg/m2) 24.1 (4.7) 23.2 (4.6) 23.9 (4.3)
Karnofsky* 60 (50–70) 60 (40–70) 70 (50–80)
Time on opioids (months)* 1 (0–4) 1 (0–4) 1 (0–4.5)
24 hourly opioid dose* 60 mg (40–120 mg) 50 µg (25 –75 µg) 60 mg (40–120 mg)
The population characteristics of the three cohorts of patients on opioids in the European Palliative Outcomes Study (mean (SD), median
(IQR*) or n (%)).
*IQR=(Lower quartile−upper quartile).
Table 2 The significant single nucleotide polymorphisms for the recessive mode of inheritance for morphine users (Fisher’s
exact test) and the frequency of these minor alleles
Morphine p Value Variant n (%)
ARRB2_rs3786047 0.0010 AA vs (AG+GG) 77 (9.6)
ARRB2_rs2036657 0.0045 GG vs (AG+AA) 79 (9.9)
ARRB2_rs2271167 0.0052 AA vs (AG+GG) 77 (9.9)
ARRB2_rs1045280 0.0069 CC vs (CT+TT) 81 (10.1)
HTR3B_rs7103572 0.0070 TT vs (CC+TC) 48 (8.2)
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DISCUSSION
In this study, people taking morphine for cancer pain
and with both rs7103572 allele variants of the 5HT3B
gene were three times more likely to have more intense
breathlessness having controlled for other available
factors. This ﬁnding was not mirrored in those taking
oxycodone or fentanyl.
Breathlessness, like pain, is a phenotype with complex
biological interactions.16 Studies have shown only weak
associations between the underlying aetiology of breath-
lessness, the descriptors of sensation and a tailored treat-
ment for breathlessness.26 The degree of physiological
impairment (such as hypoxaemia or forced expiratory
volume in 1 s) and a person’s subjective sensation of
breathlessness are weakly correlated and do not explain
much of the interindividual and intraindividual varia-
tions observed with the subjective sensation of breath-
lessness.27 Therefore, other factors need to be identiﬁed
that help to understand the variations in the beneﬁts
and toxicities of people’s clinical responses. Identifying
potential factors associated with response, such as the
HTR3B, has the potential to help reconcile clinical
experience with objective factors that explain population
differences. It is likely that several factors contribute to
the reported threefold variation in breathlessness
response to morphine observed in the dose titration
study.11 Other, as yet unknown factors, must be contrib-
uting to this variation in response to opioids, so any
factor that helps to unravel variations in response of
breathlessness to opioids is likely to be of value to clini-
cians and researchers given the paucity of such factors
currently. These current ﬁndings of one potential SNP
would form the basis of a prospective study in which
opioids were introduced to people with refractory
breathlessness in order to determine if this SNP could
be used to predict response.
Are these ﬁndings biologically plausible? The HTR3B
gene is responsible for the synthesis of the serotonergic
5-hydroxytryptamine (5HT)3B subtype receptor. There is
at least one potential explanation of how opioids may
inﬂuence the serotonergic system. The original recogni-
tion that there was more than one 5HT receptor was, in
part, by demonstrating that morphine was a weak 5HT
receptor antagonist,28 and was initially, therefore, named
the ‘M’ variant. Cocaine and methadone were simultan-
eously identiﬁed as weak 5HT antagonists.28 Recently,
the M variant was recognised as the 5HT3 receptor.
29
Even recent work has now identiﬁed ﬁve variants of
5HT3 receptors, the most prevalent of which are A and
B. The gene coding for 5HT3B (HTR3B) is found on
chromosome 11. The 5HT3B receptors are found
throughout the brain except the cerebellum.30 While
morphine is an inhibitor of the orthosteric ligand
binding site of the 5HT3 ion channel complex, by con-
trast, fentanyl appears not to have an effect on 5HT3
receptors.31 It is therefore biologically plausible that
genetic variations in 5HT3B may variably modulate
morphine-related changes in breathlessness perception
while fentanyl has no effect. This hypothesis also sup-
ports a recent study showing that another SNP of
HTR3B, rs227607 is associated with myalgia score in
statin users.32
Worsening performance status was the only other
factor that was associated with more intense breathless-
ness in the multivariable analyses. Previous population-
based studies have demonstrated worsening breathless-
ness as functional status deteriorates,33 even in the
absence of demonstrable cardiorespiratory disease.5 For
some patients, it appears that breathlessness is induced
by a physical inability to breathe because of the loss of
respiratory muscles.34
This is a study in a large clinical population using
opioids for pain where a range of symptoms were
recorded. Symptom assessment used validated tools,19
although any interaction between symptoms is poorly
understood.35 The study relies on a Likert scale for
measuring breathlessness. Widely used assessment tools
including EORTC QLQC 30 and 15, and the Functional
Assessment Cancer Treatment tools use Likert scales as
their measure.34 36 Symptoms are measured over the last
week using EORTC QLQ C-30, but medications reported
over the last 24 h. It is unlikely that this difference has a
material effect on the relationship being sought in this
exploratory study. Although visual analogue scales, or
Table 3 Association between breathlessness and confounders for the recessive mode of inheritance in the morphine
population
Univariable analysis Multivariable analysis
OR (95% CI) p Value OR p Value
HTR3B_rs7103572 2.86 (1.31 to 6.21) 0.008 2.86 (1.46 to 5.62) 0.002
ARRB2_rs1045280 0.846 (0.59 to 1.22) 0.36 0.97 (0.62 to 1.62) 0.89
Age (per year) 1.00 (0.99 to 1.01) 0.90 1.00 (0.98 to 1.02) 0.73
Male gender 1.05 (0.84 to 1.31) 0.69 1.06 (0.78 to 1.45) 0.70
Body mass index (per 1 kg/m2) 1.03 (0.98 to 1.08) 0.32 1.03 (0.97 to 1.09) 0.39
Karnofsky status (per 1 point) 0.83 (0.75 to 0.92) <0.001 0.83 (0.72 to 0.96) 0.011
Time on opioids (per month) 0.99 (0.97 to 1.00) 0.17 0.99 (0.97 to 1.00) 0.15
Morphine daily dose (per 100 mg increments) 1.00 (1.00 to 1.00) 0.17 1.00 (1.00 to 1.00) 0.469
Pain 1.19 (1.03 to 1.39) 0.022 1.13 (0.84 to 1.52) 0.41
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Borg scales, may be preferable in this population, Likert
scales for reviews of large numbers of symptoms are a
reasonable approach.37 It is also worth noting that these
screening tools make no distinction between the affect-
ive component of breathlessness (unpleasantness) and
its intensity (severity).27 Any prospective study would
need to separate these two components of breathless-
ness and reﬂect the person’s emotional response.
Strengths of the study
Many genetic association studies have not been reprodu-
cible. By contrast, the current study has several key
strengths that increase conﬁdence in the ﬁnding that a
particular SNP might inﬂuence morphine-induced
modulation of the sensation of breathlessness:
▸ A plausible biological mechanism;
▸ Large number of patients (including enough to
include relevant clinical and demographic covariates
in the analytic models);
▸ A study population broadly representative of people
with advanced cancer;
▸ A large number of genes and candidate SNPs;
▸ Rigorous statistical methods to deal with the problem
of multiplicity;
▸ Seeking a signal that is sufﬁcient to be clinically
meaningful;
▸ Use of well-validated assessment tools in rigorously
translated versions for the participating countries.
Limitations
The study did not specify a particular mode of inherit-
ance as primary, and therefore, our results do not
control the FWE within the population. The study
addressed this by creating sensitivity analyses that aggre-
gated all comparisons for different modes of inheritance
with each population and applied the BH procedure for
multiple comparisons. As such, the study did not ﬁnd
any other signiﬁcant SNPs until the FDR was set at 50%
or greater.
This study only explored individual candidate SNPs
and did not explore gene–gene interactions. A negative
result does not rule out important SNPs on other parts
of candidate genes or on other genes. The study does
not contribute to candidate SNPs for the perception of
breathlessness itself, only the degree of perception of
breathlessness while on opioids for pain.
The change in symptom severity in this cross-sectional
study population is unknown, and we are therefore
unable to draw conclusions about breathlessness response
to opioids. Only longitudinal studies before and after
the introduction of opioids for breathlessness can fully
answer this question. Some respondents with breathless-
ness may have partially responded to opioids for the
intensity of their breathlessness, and be much worse
without them, others may not have responded to opioids
at all, and yet others with no breathlessness may have
had none prior to starting opioids.
Implications for further research
There is a need to replicate these ﬁndings in a similar
independent cohort. There would be an argument for
using one of the newer, more comprehensive measures of
breathlessness that includes measures of severity, unpleas-
antness and the person’s emotional response.38 39 Using
such measurement tools would allow for a more nuanced
exploration of the response to opioids for breathlessness.
Genome-wide association studies may identify genetic
variations that are important in the explanation of
varying responses of breathlessness to opioids as these
studies become more affordable.
CONCLUSIONS
This large, exploratory study identiﬁed one SNP asso-
ciated with higher levels of breathlessness in people
taking morphine for pain, but not in those taking fen-
tanyl or oxycodone. The study does not help to under-
stand any genetic variations associated with the
perception of breathlessness per se, but provides a can-
didate SNP for further evaluation in prospective studies
of people before and after morphine is introduced to
reduce the perception of breathlessness.
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